Expert Discussion: ASCO 2022

[摘要] Wimmer: The long-awaited results regarding OSshowed only a numerical benefit that did not reach levelof significance. One third of the patients had missing dataregarding overall survival due to lost to follow-up or withdrawal of consent, which limited the assessment of theOS.Nevertheless, it can be excepted that all possible subgroups had been investigated in the hope of detecting OSdifferences between patients in the treatment and thecontrol arm. Even in a subgroup analysis including patients with longer follow-ups, they only observed a trendof improved OS. As a side note: the PALOMA-2 trial metits primary endpoint of significantly improved PFS; nevertheless, a significant OS benefit could not be presentedat the ASCO 2022.

[学科分类] 泌尿医学